MedTrace Logo

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

NCT00004261 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-02-22

No results posted yet for this study

Summary

RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective cancer treatment.

PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen in tumor cells of patients who are undergoing surgery or biopsy for breast, prostate, or cervical cancer or high grade soft tissue sarcoma.

Conditions

Interventions

DRUG

EF5

OTHER

flow cytometry

OTHER

fluorescent antibody technique

OTHER

immunohistochemistry staining method

PROCEDURE

biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Anthony Fyles, MD · Princess Margaret Hospital, Canada

Study Design

Purpose
DIAGNOSTIC

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Primary Completion
2002-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004261 on ClinicalTrials.gov